Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials

Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus

(2011) Jose Pablo Maroto et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma

(2010) Dorothy A. White et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

(2010) J. N. Sarkaria et al.   CLINICAL CANCER RESEARCH

Past, Present and Future of Targeted Therapy in Solid Tumors

(2010) A. Palazzo et al.   CURRENT CANCER DRUG TARGETS

Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity

(2009) L J Coleman et al.   BRITISH JOURNAL OF CANCER

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

Eukaryotic Initiation Factor-4E and Cyclin D1 Expression Associated with Patient Survival in Lung Cancer

(2009) Thaer Khoury et al.   Clinical Lung Cancer

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

(2009) Susan L. Ellard et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors

(2008) Bobbak Vahid et al.   CHEST

Everolimus-related Pulmonary Toxicity in Heart Transplant Recipients

(2008) Victor Expósito et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION